| Identification | Back Directory | [Name]
3',4',5,7-TETRAHYDROXYISOFLAVONE | [CAS]
480-23-9 | [Synonyms]
OROBOL
isoluteolin
3'-Hydroxygenistein
3',4',5,7-TETRAHYDROXYISOFLAVONE
3’,4’,5,7-tetrahydroxy-isoflavon
5,7,3’,4’-tetrahydroxyisoflavone
3',4',5,7-Tetrahydroxyisoflavone Orobol
5,7-dihydroxy-3-(3,4-dihydroxyphenyl)-4h-1-benzopyran-4-on
5,7-dihydroxy-3-(3,4-dihydroxyphenyl)-4h-1-benzopyran-4-one
3-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one, 3-(3,4-dihydroxyphenyl)-5,7-dihydroxy- | [Molecular Formula]
C15H10O6 | [MDL Number]
MFCD00210595 | [MOL File]
480-23-9.mol | [Molecular Weight]
286.24 |
| Chemical Properties | Back Directory | [Melting point ]
270 °C | [Boiling point ]
616.1±55.0 °C(Predicted) | [density ]
1.654±0.06 g/cm3(Predicted) | [solubility ]
Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | [form ]
powder | [pka]
6.37±0.20(Predicted) | [color ]
Yellow | [Cosmetics Ingredients Functions]
ANTIOXIDANT |
| Hazard Information | Back Directory | [Uses]
Orobol is one of the major soy isoflavones and has various pharmacological activities, including anti-skin-aging and anti-obesity effects. Orobol inhibits CK1ε, VEGFR2, MAP4K5, MNK1, MUSK, TOPK, and TNIK (IC50=1.24-4.45 μM). Orobol also inhibits PI3K isoforms (IC50=3.46-5.27 μM for PI3K α/β/γ/K/δ)[1][2]. | [Definition]
ChEBI: Orobol is a member of the class of 7-hydroxyisoflavones which consists of isoflavone substituted by hydroxy groups at positions 5, 7, 3' and 4'. It has been isolated from the mycelia of Cordyceps sinensis. It has a role as an anti-inflammatory agent, a radical scavenger, a plant metabolite and a fungal metabolite. It is functionally related to an isoflavone. | [in vivo]
Orobol attenuates high fat diet-induced weight gain and lipid accumulation without affecting food intake in C57BL/6J mice[2]. | Animal Model: | HFD-induced obesity in C57BL/6J mice[2] | | Dosage: | 10?mg/kg | | Administration: | Intragastrically; daily for 23 weeks | | Result: | Significantly reduced body weight by 17.3% compared to the HFD group.
|
| [target]
PI3K | Caspase | Bcl-2/Bax | Calcium Channel | Antifection | Influenza virus | [References]
[1] Kim MH, et al. Lipid Nanoparticles for Enhancing the Physicochemical Stability and Topical Skin Delivery of Orobol. Pharmaceutics. 2020;12(9):845. Published 2020 Sep 3. DOI:10.3390/pharmaceutics12090845 |
|
| Company Name: |
BioBioPha Co., Ltd.
|
| Tel: |
0871-65217109 13211707573; |
| Website: |
http://www.biobiopha.com |
|